GlassScriptPhysician profile
Casey N Tribble
NPI 1649639253
$7,428.67
in general payments reported to CMS, 2019-2025
32 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,056 · 2022: $1,304 · 2023: $1,641 · 2024: $1,253 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,021 · Education: $48.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,020.76 |
| Education | $48.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,137.50 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $736.85 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $722.67 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $702.74 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $574.27 | 2021-2024 | Xarelto |
| Boston Scientific Corporation | $475.65 | 2021-2025 | Watchman Flx, Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $424.91 | 2021-2025 | Lifevest |
| Pfizer INC. | $375.21 | 2021-2025 | |
| Irhythm Technologies, INC. | $290.21 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Abbott Laboratories | $258.60 | 2021-2023 | Cardiomems |
| Alnylam Pharmaceuticals INC. | $206.73 | 2024-2025 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $174.40 | 2023-2024 | Inpefa |
| Kestra Medical Technology Services, INC. | $155.61 | 2023-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $151.53 | 2024-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $147.29 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $143.33 | 2021-2025 | Farxiga |
| Esperion Therapeutics, INC. | $119.72 | 2021-2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $108.12 | 2021-2022 | |
| Medtronic, INC. | $101.76 | 2023-2025 | Linq II |
| Bayer Healthcare Pharmaceuticals INC. | $85.20 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $68.14 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $61.60 | 2021-2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $38.23 | 2023 | |
| Philips North America LLC | $27.66 | 2025 | Neoview, Mcot |
| Impulse Dynamics (USA) INC. | $24.64 | 2023 | Optimizer |
| Regeneron Healthcare Solutions, INC. | $20.94 | 2025 | Evkeeza |
| Amryt Pharma Holdings LTD | $20.81 | 2021 | |
| Daiichi Sankyo INC. | $19.77 | 2024 | Injectafer |
| Baxter Healthcare | $17.53 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Glaxosmithkline, LLC. | $16.25 | 2025 | Shingrix |
| Chiesi USA, INC. | $16.09 | 2023 | Kengreal |
| Sumitomo Pharma America, INC. | $4.71 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Tribble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.